IGF-1 signaling in neonatal hypoxia-induced pulmonary hypertension: Role of epigenetic regulation

Vascular Pharmacology

Volumn 73, Issue , 2015, Pages 20-31

  Yang, Qiwei ^a,c   Sun, Miranda ^a   Ramchandran, Ramaswamy ^a   Raj, J Usha ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

DNA methylation; Endothelin 1; Histone deacetylase; IGF 1; Neonatal hypoxia; Pulmonary hypertension

Indexed keywords

APICIDIN; COMPLEMENTARY DNA; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR TYPE A; ENDOTHELIN RECEPTOR TYPE B; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IGF1 PROTEIN, HUMAN; INSULIN-LIKE GROWTH FACTOR-1, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CHRONIC DISEASE; CONTROLLED STUDY; DNA METHYLATION; DNA SYNTHESIS; DOWN REGULATION; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; EPIGENETICS; GENE SILENCING; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HYPOXIA-INDUCED PULMONARY HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PULMONARY ARTERY SMOOTH MUSCLE CELL; RNA ISOLATION; SIGNAL TRANSDUCTION; THICKNESS; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; ANIMAL; ARTERIAL PRESSURE; C57BL MOUSE; CELL CULTURE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSFECTION; GENETICS; HYPERTENSION, PULMONARY; HYPOXIA; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PULMONARY ARTERY; RNA INTERFERENCE; TIME FACTOR; VASCULAR REMODELING;

ANIMALS; ANIMALS, NEWBORN; ARTERIAL PRESSURE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA METHYLATION; ENDOTHELIN-1; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; HYPOXIA; INSULIN-LIKE GROWTH FACTOR I; MICE, INBRED C57BL; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; PULMONARY ARTERY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; VASCULAR REMODELING;

EID: 84941730816     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.04.005     Document Type: Article

References (43)

1. Jones R.D., Morice A.H., Emery C.J. Effects of perinatal exposure to hypoxia upon the pulmonary circulation of the adult rat. Physiol Res 2004, 53:11-17.
2. Yang Q., Sun M. Perinatal and neonatal hypoxia in pulmonary vascular dysfunction. Cardiol Pharmacol 2013, 3:e123.
3. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater?. J Natl Cancer Inst 2012, 104:975-981.
4. Arcaro A. Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol 2013, 4:30.
5. Vincent E.E., Elder D.J., Curwen J., Kilgour E., Hers I., Tavare J.M. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor. PLoS One 2013, 8:e66963.
6. Yang Y., Yee D. Targeting insulin and insulin-like growth factor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2012, 17:251-261.
7. Limesand K.H., Chibly A.M., Fribley A. Impact of targeting insulin-like growth factor signaling in head and neck cancers. Growth Horm IGF Res 2013, 23:135-140.
8. Yang Q.W., Liu S., Tian Y., Salwen H.R., Chlenski A., Weinstein J., et al. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 2003, 63:6299-6310.
9. Yang Q., Tian Y., Liu S., Zeine R., Chlenski A., Salwen H.R., et al. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 2007, 67:1716-1724.
10. Cavasin M.A., Demos-Davies K., Horn T.R., Walker L.A., Lemon D.D., Birdsey N., et al. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res 2012, 110:739-748.
11. Zhao L., Chen C.N., Hajji N., Oliver E., Cotroneo E., Wharton J., et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 2012, 126:455-467.
12. Ambalavanan N., Nicola T., Hagood J., Bulger A., Serra R., Murphy-Ullrich J., et al. Transforming growth factor-beta signaling mediates hypoxia-induced pulmonary arterial remodeling and inhibition of alveolar development in newborn mouse lung. Am J Physiol Lung Cell Mol Physiol 2008, 295:L86-L95.
13. Nicola T., Ambalavanan N., Zhang W., James M.L., Rehan V., Halloran B., et al. Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Am J Physiol Lung Cell Mol Physiol 2011, 301:L125-L134.
14. Bierer R., Nitta C.H., Friedman J., Codianni S., de Frutos S., Dominguez-Bautista J.A., et al. NFATc3 is required for chronic hypoxia-induced pulmonary hypertension in adult and neonatal mice. Am J Physiol Lung Cell Mol Physiol 2011, 301:L872-L880.
15. Young K.C., Torres E., Hatzistergos K.E., Hehre D., Suguihara C., Hare J.M. Inhibition of the SDF-1/CXCR4 axis attenuates neonatal hypoxia-induced pulmonary hypertension. Circ Res 2009, 104:1293-1301.
16. Sartina E., Suguihara C., Ramchandran S., Nwajei P., Rodriguez M., Torres E., et al. Antagonism of CXCR7 attenuates chronic hypoxia-induced pulmonary hypertension. Pediatr Res 2012, 71:682-688.
17. Blood A.B., Terry M.H., Merritt T.A., Papamatheakis D.G., Blood Q., Ross J.M., et al. Effect of chronic perinatal hypoxia on the role of rho-kinase in pulmonary artery contraction in newborn lambs. Am J Physiol Regul Integr Comp Physiol 2013, 304:R136-R146.
18. Dumitrascu R., Weissmann N., Ghofrani H.A., Dony E., Beuerlein K., Schmidt H., et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006, 113:286-295.
19. Peyter A.C., Muehlethaler V., Liaudet L., Marino M., Di Bernardo S., Diaceri G., et al. Muscarinic receptor M1 and phosphodiesterase 1 are key determinants in pulmonary vascular dysfunction following perinatal hypoxia in mice. Am J Physiol Lung Cell Mol Physiol 2008, 295:L201-L213.
20. Chi A.Y., Waypa G.B., Mungai P.T., Schumacker P.T. Prolonged hypoxia increases ROS signaling and RhoA activation in pulmonary artery smooth muscle and endothelial cells. Antioxid Redox Signal 2010, 12:603-610.
21. Johnson B.A., Lowenstein C.J., Schwarz M.A., Nakayama D.K., Pitt B.R., Davies P. Culture of pulmonary microvascular smooth muscle cells from intraacinar arteries of the rat: characterization and inducible production of nitric oxide. Am J Respir Cell Mol Biol 1994, 10:604-612.
22. Shah M.Y., Vasanthakumar A., Barnes N.Y., Figueroa M.E., Kamp A., Hendrick C., et al. DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Res 2010, 70:5840-5850.
23. Olave N., Nicola T., Zhang W., Bulger A., James M., Oparil S., et al. Transforming growth factor-beta regulates endothelin-1 signaling in the newborn mouse lung during hypoxia exposure. Am J Physiol Lung Cell Mol Physiol 2012, 302:L857-L865.
24. Tang J.R., Le Cras T.D., Morris K.G., Abman S.H. Brief perinatal hypoxia increases severity of pulmonary hypertension after reexposure to hypoxia in infant rats. Am J Physiol Lung Cell Mol Physiol 2000, 278:L356-L364.
25. Mulvihill M.J., Cooke A., Rosenfeld-Franklin M., Buck E., Foreman K., Landfair D., et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2009, 1:1153-1171.
26. Kim J.S., Kim E.S., Liu D., Lee J.J., Solis L., Behrens C., et al. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer 2014, 15:213-221.
27. Hirakawa T., Yashiro M., Murata A., Hirata K., Kimura K., Amano R., et al. IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer. BMC Cancer 2013, 13:392.
28. Zinkhan E.K., Fu Q., Wang Y., Yu X., Callaway C.W., Segar J.L., et al. Maternal hyperglycemia disrupts histone 3 lysine 36 trimethylation of the IGF-1 gene. J Nutr Metab 2012, 2012:930364.
29. Tosh D.N., Fu Q., Callaway C.W., McKnight R.A., McMillen I.C., Ross M.G., et al. Epigenetics of programmed obesity: alteration in IUGR rat hepatic IGF1 mRNA expression and histone structure in rapid vs. delayed postnatal catch-up growth. Am J Physiol Gastrointest Liver Physiol 2010, 299:G1023-G1029.
30. Fu Q., Yu X., Callaway C.W., Lane R.H., McKnight R.A. Epigenetics: intrauterine growth retardation (IUGR) modifies the histone code along the rat hepatic IGF-1 gene. FASEB J 2009, 23:2438-2449.
31. Nordin M., Bergman D., Halje M., Engstrom W., Ward A. Epigenetic regulation of the Igf2/H19 gene cluster. Cell Prolif 2014, 47:189-199.
32. Hertel J., Hirche C., Wissmann C., Ebert M.P., Hocker M. Transcription of the vascular endothelial growth factor receptor-3 (VEGFR3) gene is regulated by the zinc finger proteins Sp1 and Sp3 and is under epigenetic control: transcription of vascular endothelial growth factor receptor 3. Cell Oncol 2014, 37:131-145.
33. Dahal B.K., Cornitescu T., Tretyn A., Pullamsetti S.S., Kosanovic D., Dumitrascu R., et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med 2010, 181:158-167.
34. Chanakira A., Dutta R., Charboneau R., Barke R., Santilli S.M., Roy S. Hypoxia differentially regulates arterial and venous smooth muscle cell proliferation via PDGFR-beta and VEGFR-2 expression. Am J Physiol Heart Circ Physiol 2012, 302:H1173-H1184.
35. Grimminger F., Schermuly R.T. PDGF receptor and its antagonists: role in treatment of PAH. Adv Exp Med Biol 2010, 661:435-446.
36. Schiffrin E.L. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 1995, 25:1135-1143.
37. Ambalavanan N., Bulger A., Murphy-Ullrich J., Oparil S., Chen Y.F. Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling. Pediatr Res 2005, 57:631-636.
38. Kapakos G., Bouallegue A., Daou G.B., Srivastava A.K. Modulatory role of nitric oxide/cGMP system in endothelin-1-induced signaling responses in vascular smooth muscle cells. Curr Cardiol Rev 2010, 6:247-254.
39. MacLean M.R., McCulloch K.M., Baird M. Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J Cardiovasc Pharmacol 1994, 23:838-845.
40. Ivy D., McMurtry I.F., Yanagisawa M., Gariepy C.E., Le Cras T.D., Gebb S.A., et al. Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol 2001, 280:L1040-L1048.
41. Sun M., Yang Q. Neonatal hyperoxia and pulmonary hypertension. Pediatr Neonatal Nurs Open J 2014, 1:1-5.
42. Watson J.A., Watson C.J., McCrohan A.M., Woodfine K., Tosetto M., McDaid J., et al. Generation of an epigenetic signature by chronic hypoxia in prostate cells. Hum Mol Genet 2009, 18:3594-3604.
43. Yang Q., Lu Z., Ramchandran R., Longo L.D., Raj J.U. Pulmonary artery smooth muscle cell proliferation and migration in fetal lambs acclimatized to high-altitude long-term hypoxia: role of histone acetylation. Am J Physiol Lung Cell Mol Physiol 2012, 303:L1001-L1010.